Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Zillow Group Inc Class C — how do they compare? Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B), while Zillow Group Inc Class C trades at $34.1 (market cap $7.60B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 17.5× Zillow Group Inc Class C's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals.
| VRTX | Z | |
|---|---|---|
Market Cap | $132.79B | $7.60B |
Sector | Health | Media |
52-Week High | $529.65 | $90.35 |
52-Week Low | $376.62 | $29.41 |
Enterprise Value | $126.92B | $7.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Zillow Group (Z) trades at $33.61, up 0.54% on the day, amid a challenging real estate market. The stock faces a bearish technical signal with support at $33 and resistance at $34. Fundamentally, the company shows improving revenue and a return to profitability in 2025, with a net income of $23 million, though valuation ratios like a P/E of 146.74 remain high. Recent news is dominated by a securities class action lawsuit with a deadline of August 10, 2026, creating significant headline risk.
The outlook is cautious. While analyst consensus is a Buy with a $47.00 price target, indicating potential upside, near-term risks from the lawsuit and a bearish technical picture suggest volatility. Investment opportunity hinges on the company's ability to sustain revenue growth and improve margins, but investors must weigh the legal overhang and high valuation against the positive earnings trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
